Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
ConditionRelapsed B-Cell Non Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorImmunityBio, Inc.
About this trial
Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Eligibility criteria
Qualifiers
Have completed ≥2 lines of cytotoxic chemotherapy.
Have received rituximab or another anti-CD20 antibody.
Have measurable disease by Lugano classification documented within 8 weeks of the time of consent, defined as nodal lesions >15 mm in the long axis or extranodal lesions >10 mm in long and short axis, or bone marrow involvement that is biopsy proven.
Disqualifiers
Histologically documented primary CNS lymphoma, CLL, Burkitt, Burkitt-like lymphoma.
Known hypersensitivity or allergy to any component of the study medications, including sulfa-containing study medication(s) (e.g., albumin [human], dimethyl sulfoxide [DMSO]).
ANC < 1000 cells/mm3.
Platelet count < 100,000 cells/mm3.
Trial design
Treatments tested in this trial
- CD19 t-haNK- IV Administration
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov